top of page

Latest News

Dec 4, 2024

Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It

https://glycyx.reportablenews.com/pr/opioid-suppressive-impact-on-immune-checkpoint-inhibitors

Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It
Read More

Apr 25, 2020

Glycyx MOR Inc. completes license agreement with Theravance Biopharma Inc for Axelopran

SAN FRANCISCO, April 25, 2020. Glycyx MOR Inc. a company focused on extending life in severe illness has entered into a licensing agreement with Theravance Biopharma for axelopran for development and commercialization of globally.

Glycyx MOR Inc. completes license agreement with Theravance Biopharma Inc for Axelopran
Read More
bottom of page